CD155-TIGIT Axis as a Therapeutic Target for Cancer Immunotherapy

被引：3

作者：

Mu, Yeteng ^{[1
,2
]}

Guan, Xingang ^{[1
]}

机构：

[1] Taizhou Univ, Sch Med, Dept Basic Med, Taizhoum 318000, Zhejiang, Peoples R China

[2] Beihua Univ, Sch Med Technol, Jilin 132013, Jilin, Peoples R China

来源：

CURRENT MEDICINAL CHEMISTRY | 2024年 / 31卷 / 13期

关键词：

TIGIT; CD155; PD-1; immune checkpoint inhibitor; cancer immunotherapy; tumor cells; CD8(+) T-CELLS; NECTIN-LIKE PROTEINS; GROWTH-FACTOR; TIGIT; MELANOMA; BLOCKADE; RECEPTOR; DNAM-1; PD-1; EXPRESSION;

D O I：

10.2174/0929867330666230324152532

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Immune checkpoint inhibitors (ICIs) have shown unprecedented efficacy in treating many advanced cancers. Although FDA-approved ICIs have shown promising efficacy in treating many advanced cancers, their application is greatly limited by the low response rate, immune-related adverse events (irAE), and drug resistance. Developing novel ICIs holds great promise to improve the survival and prognosis of advanced cancer patients. T-Cell immunoglobulin and ITIM domain (TIGIT) is an inhibitory receptor expressed on T cells, natural killer (NK) cells, and T regulatory cells. Increasing reports have shown that the disrupting CD155-TIGIT axis could activate the immune system and restore antitumor immune response. This review briefly summarized the role of TIGIT in tumor immune escape and targeting CD155-TIGIT axis drugs in preclinical and clinical trials for cancer immunotherapy.

引用

页码：1634 / 1645

页数：12

共 50 条

[31] TIGIT: a novel immunotherapy target moving from bench to bedside [J].

Solomon, Benjamin L. ;

Garrido-Laguna, Ignacio .

CANCER IMMUNOLOGY IMMUNOTHERAPY, 2018, 67 (11) :1659-1667

[32] Targeting the TIGIT-PVR immune checkpoint axis as novel therapeutic option in breast cancer [J].

Stamm, Hauke ;

Oliveira-Ferrer, Leticia ;

Grossjohann, Eva-Maria ;

Muschhammer, Jana ;

Thaden, Vanessa ;

Brauneck, Franziska ;

Kischel, Roman ;

Mueller, Volkmar ;

Bokemeyer, Carsten ;

Fiedler, Walter ;

Wellbrock, Jasmin .

ONCOIMMUNOLOGY, 2019, 8 (12)

[33] Cancer immunotherapy targeting the CD47/SIRPα axis [J].

Weiskopf, Kipp .

EUROPEAN JOURNAL OF CANCER, 2017, 76 :100-109

[34] CD155 and Its Receptors as Targets for Cancer Therapy [J].

Paolini, Rossella ;

Molfetta, Rosa .

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (16)

[35] ICOS-L as a Potential Therapeutic Target for Cancer Immunotherapy [J].

Marinelli, Oliviero ;

Nabissi, Massimo ;

Morelli, Maria Beatrice ;

Torquati, Luciana ;

Amantini, Consuelo ;

Santoni, Giorgio .

CURRENT PROTEIN & PEPTIDE SCIENCE, 2018, 19 (11) :1107-1113

[36] CD155 immunoregulation as a target for natural killer cell immunotherapy in glioblastoma [J].

Kyle B. Lupo ;

Sandro Matosevic .

Journal of Hematology & Oncology, 13

[37] Glutaminyl cyclase is an enzymatic modifier of the CD47-SIRPα axis and a target for cancer immunotherapy [J].

Logtenberg, Meike E. W. ;

Jansen, J. H. Marco ;

Raaben, Matthijs ;

Toebes, Mireille ;

Franke, Katka ;

Brandsma, Arianne M. ;

Matlung, Hanke L. ;

Fauster, Astrid ;

Gomez-Eerland, Raquel ;

Bakker, Noor A. M. ;

van der Schot, Simone ;

Marijt, Koen A. ;

Verdoes, Martijn ;

Haanen, John B. A. G. ;

van den Berg, Joost H. ;

Neefjes, Jacques ;

van den Berg, Timo K. ;

Brummelkamp, Thijn R. ;

Leusen, Jeanette H. W. ;

Scheeren, Ferenc A. ;

Schumacher, Ton N. .

NATURE MEDICINE, 2019, 25 (04) :612-+

[38] The CD112R/CD112 axis: a breakthrough in cancer immunotherapy [J].

Zeng, Taofei ;

Cao, Yuqing ;

Jin, Tianqiang ;

Tian, Yu ;

Dai, Chaoliu ;

Xu, Feng .

JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2021, 40 (01)

[39] Repositioning liothyronine for cancer immunotherapy by blocking the interaction of immune checkpoint TIGIT/PVR [J].

Zhou, Xiuman ;

Du, Jiangfeng ;

Wang, Hongfei ;

Chen, Chunxia ;

Jiao, Ling ;

Cheng, Xiangrui ;

Zhou, Xiaowen ;

Chen, Shaomeng ;

Gou, Shanshan ;

Zhao, Wenshan ;

Zhai, Wenjie ;

Chen, Junhui ;

Gao, Yanfeng .

CELL COMMUNICATION AND SIGNALING, 2020, 18 (01)

[40] Interaction of PVR/PVRL2 with TIGIT/DNAM-1 as a novel immune checkpoint axis and therapeutic target in cancer [J].

Stamm, Hauke ;

Wellbrock, Jasmin ;

Fiedler, Walter .

MAMMALIAN GENOME, 2018, 29 (11-12) :694-702

← 1 2 3 4 5 →